Regarding studies testing the effects of GLP-1 analogues in cognitive disorders, a double-blinded placebo-controlled trial with liraglutide given for 12 weeks in late middle-aged individuals (age range 45–70) with subjective cognitive complaints, half of whom had a family history of AD, showed no cognitive benefits [90]. This evidence concerns the gene GLP1R and Alzheimer disease.